Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Titan Pharmaceuticals, Inc. (TTNP : NSDQ)
 
 • Company Description   
Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

Number of Employees: 11

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.50 Daily Weekly Monthly
20 Day Moving Average: 234,093 shares
Shares Outstanding: 12.04 (millions)
Market Capitalization: $6.04 (millions)
Beta: 0.73
52 Week High: $3.10
52 Week Low: $0.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -38.56% -32.67%
12 Week -52.64% -48.61%
Year To Date -50.78% -41.47%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
400 OYSTER POINT BLVD SUITE 505
-
SAN FRANCISCO,CA 94080
USA
ph: 650-244-4990
fax: 650-244-4956
skilmer@titanpharm.com http://www.titanpharm.com
 
 • General Corporate Information   
Officers
Marc Rubin - Executive Chairman
Katherine Beebe DeVarney - President; Chief Operating Officer and Director
Brian E. Crowley - Vice President; Finance
Joseph A. Akers - Director
M. David MacFarlane - Director

Peer Information
Titan Pharmaceuticals, Inc. (CORR.)
Titan Pharmaceuticals, Inc. (RSPI)
Titan Pharmaceuticals, Inc. (CGXP)
Titan Pharmaceuticals, Inc. (BGEN)
Titan Pharmaceuticals, Inc. (GTBP)
Titan Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 888314606
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 05/16/22
Share - Related Items
Shares Outstanding: 12.04
Most Recent Split Date: 12.00 (0.03:1)
Beta: 0.73
Market Capitalization: $6.04 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/16/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.97
Price/Cash Flow: -
Price / Sales: 3.96
EPS Growth
vs. Year Ago Period: 87.35%
vs. Previous Quarter: 20.83%
Sales Growth
vs. Year Ago Period: -90.66%
vs. Previous Quarter: -48.86%
ROE
03/31/22 - -
12/31/21 - -120.37
09/30/21 - -102.72
ROA
03/31/22 - -
12/31/21 - -87.86
09/30/21 - -70.99
Current Ratio
03/31/22 - -
12/31/21 - 2.71
09/30/21 - 4.59
Quick Ratio
03/31/22 - -
12/31/21 - 2.60
09/30/21 - 4.53
Operating Margin
03/31/22 - -
12/31/21 - -618.41
09/30/21 - -269.43
Net Margin
03/31/22 - -
12/31/21 - -575.10
09/30/21 - -328.67
Pre-Tax Margin
03/31/22 - -
12/31/21 - -575.10
09/30/21 - -246.12
Book Value
03/31/22 - -
12/31/21 - 0.52
09/30/21 - 0.76
Inventory Turnover
03/31/22 - -
12/31/21 - 1.04
09/30/21 - 3.34
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©